Ulf Sengutta’s Post

CelluSPOT Synthese im Peptidsynthesizer MultiPep 2 Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers https://lnkd.in/eGFnuFwJ #Peptode #peptide #peptidsynthesizer #peptidesynthesis #CelluSPOT #Multipep #CEM #Intavis

CelluSPOT Synthese im Peptidsynthesizer MultiPep 2 Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers https://lnkd.in/euSWUk8p #Peptode #peptide #peptidsynthesizer #peptidesynthesis #CelluSPOT #Multipep #CEM #Intavis  

New RAS dialogue! Understanding and overcoming resistance to KRAS G12C inhibitors remains a key focus in the fight against RAS-driven cancers. In a new blog post, Drs. Mira and Nokin describe non-genetic methods of resistance to G12C inhibitors that bind to the inactive, GDP-bound form of the protein. They observed an increase in active GTP-loaded KRAS in patient samples, and argue for the dual inhibition of both active and inactive KRAS as a more effective therapeutic strategy.

⏰ Time’s running out! SECURE YOUR SPOT & discover the pivotal role of functional #cellbasedassays for characterizing novel #therapeutics & biosimilars targeting #cytokines in inflammation & oncology. Hear about case studies employing Eurofins DiscoverX®’s assays for monitoring receptor dimerization & pathway activation targeting cytokines including IL-23, IL-12, IL-17, & IL-4/IL-13.  And many more learning outcomes…https://lnkd.in/g-G4exDR

Foundation Medicine and Syndax Pharmaceuticals join forces to develop a tool targeting acute myeloid leukemia (AML) patients with NPM1 mutations. NPM1 mutations are prevalent in AML, affecting about 30% of newly diagnosed patients. Currently, there are no approved targeted treatments for these patients, with a 50% overall survival rate after five years. Syndax's revumenib presents promising new treatment avenues for NPM1-mutated AML. Foundation Medicine plans to create a next-gen sequencing diagnostic on its FoundationOne® Heme platform to better identify suitable patients. If approved, this assay could revolutionize personalized AML treatment, marking Foundation Medicine's debut as a companion diagnostic provider and cementing its leadership in the field. This collaboration underscores the significance of genomic profiling and therapeutic target development in combatting blood cancers, aiming to enhance patient outcomes and treatment decisions. Learn more: https://lnkd.in/dHJNWsc8 Neil Gallagher MD PhD Norman Nagl Shaliny Kushwaha #FoundationMedicine #SyndaxPharmaceuticals #AML #CompanionDiagnostic #GenomicProfiling #BloodCancers #PrecisionMedicine

For anticancer drugs with a narrow therapeutic window, there is a delicate balance between efficacy and toxicity, thus it is pivotal to administer the right dose from the first administration onwards. Exposure of pemetrexed, a cytotoxic drug used in lung cancer treatment, is dictated by kidney function. To facilitate optimized dosing of pemetrexed, accurate prediction of drug clearance is pivotal. In the journal of anticancer chemotherapy and pharmacology Nikki Bleijs - de Rouw published her findings on endogenous biomarkers to predict pemetrexed pharmacokinetics. Nikki Bleijs - de Rouw showed that the combined CKD-EPI equation using both cystatin C and serum creatinine performed best in terms predicting pharmacokinetics of pemetrexed. This may facilitate dose individualization of pemetrexed. Read all about it here: https://lnkd.in/ehD98MUp Radboud Applied Pharmacometrics Radboudumc Radboudumc wetenschap

An application of pharmacometrics to individualize dosing of pemetrexed.

Clinical Trials Updates: Takeda's Iclusig (ponatinib) has received accelerated approval from the FDA for treating newly diagnosed adults with a rare type of leukaemia. This approval marks the first time a targeted therapy has been approved in the US as the initial treatment for Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph-positive ALL). This typeof leukaemiaa affects around 25% of adults with ALL and is identified by the presence of an abnormal gene called the Philadelphia chromosome. Iclusig, a kinase inhibitor, was previously approved in the US for various leukemia patients. This additional approval was supported by positive results from the PhALLCON study, showing Iclusig-treated patients achieved over two-fold improvement in minimal residual disease-negative complete remission. Congrats to Takeda once again for the successful approval! #medicalaffairs #clinicaldevelopment #clinicalcareers #FDAapproval #medicalcareers https://lnkd.in/efmHKAXQ

This paper suggests that a novel CEACAM6-targeted antibody–drug conjugate (ADC) named EBET for PDAC therapy. CEACAM6-EBET ADC delivers BET protein degrader via CEACAM6 antibody, Modulation of PDAC Stromal : Bystander efficacy on CEACAM6-negative Cancer-Associated Fibroblasts (CAFs) inhibits STAT3 signaling, contributing to break down of the PDAC stromal. Authors say that this dual impact on PDAC cells and stroma is a key feature. https://lnkd.in/g43BaqPm

Antibody Therapeutics, official journal of Chinese Antibody Society, published by Oxford University Press, has been indexed by ESCI, PubMed and Scopus (2023 CiteScore: 8.7). Here, we would like to highlight Top 10 most cited articles published in 2022. The 5th paper entitled “Novel development strategies and challenges for anti-Her2 antibody-drug conjugates” was contributed by Jianmin Fang from  Tongji University. Antibody-drug conjugates (ADCs) combining potent cytotoxicity of small-molecule drugs with the selectivity and excellent pharmacokinetic profile of monoclonal antibody (mAb) are promising therapeutic modalities for a diverse range of cancers. Owing to overexpression in a wide range of tumors, human epidermal growth factor receptor 2 (Her2) is one of the most utilized targeting antigens for ADCs to treat Her2-positive cancers. This review, focusing on the anti-Her2 ADCs in clinical trials or on the market, discusses the strategies to select antibody formats, the linkages between linker and mAb, and effective payloads with particular release and action mechanisms for a good clinical outcome. The article has been cited 20 times as of today. Click the link for the free access of the full text of the article: https://lnkd.in/dv8pZT8w We are also welcoming therapeutic antibody related submission through https://lnkd.in/dMJjtiD #Antibody #Therapeutics #Top10